TGA / PMDA / NMPA · Asia-Pacific
spray — TGA / PMDA / NMPA regulatory status
spray regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 4
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 48 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| 54135419SUI3003 | Phase 3 | Janssen-Cilag International N.V | 2024-518615-19-00 |
| ACP-101-302 | Phase 3 | Anaxis Pharma | 2023-506200-24-00 |
| CPT for Allergic rhinoconjunctivitis to… | Phase 3 | Anaxis Pharma | 2025-521230-29-00 |
| Carbetocin Nasal Spray | Phase 3 | Anaxis Pharma | 2023-506201-19-00 |
| D3252C00002 | Phase 3 | AstraZeneca | 2023-507987-38-00 |
| D5982C00006 | Phase 3 | AstraZeneca | 2024-513568-24-00 |
| D5982C00007 | Phase 3 | AstraZeneca | 2023-505787-11-00 |
| D5982C00008 | Phase 3 | AstraZeneca | 2023-505786-88-00 |
| Fasedienol Nasal Spray | Phase 3 | Vistagen Therapeutics | NCT06615557 |
| Fasedienol Nasal Spray | Phase 3 | Vistagen Therapeutics | NCT06358651 |
| Intranasal Fentanyl Spray (INFS) | Phase 3 | Takeda | NCT01429051 |
| Lidocaine spray | Phase 3 | Chia Tai Tianqing | NCT01505920 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 12036198 | Dosage forms and therapeutic uses of L-4-chlorokynurenine | US |
| 11612870 | Microencapsulation of chemicals and bioactives by in situ complex coacervation during spray drying | US |
| 10980758 | Dosage forms and therapeutic uses of L-4-chlorokynurenine | US |
| 10632091 | Dosage forms and therapeutic uses of L-4-chlorokynurenine | US |
| 10617663 | Dosage forms and therapeutic uses of L-4-chlorokynurenine | US |
| 10188811 | Nasal spray device | US |
| 9993453 | Dosage forms and therapeutic uses L-4-chlorokynurenine | US |
| 9993450 | Dosage forms and therapeutic uses of L-4-chlorokynurenine | US |
| 8647670 | Biocompatible rapid-gelating hydrogel and associated preparation method of spray | US |
| 8293275 | Spray freeze dry of compositions for pulmonary administration | US |
| 7972661 | Electrospraying method with conductivity control | US |
| 7279322 | Electrospraying apparatus and method for coating particles | US |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of spray?
spray currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get spray regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to spray?
This spoke lists 48 published programs associated with spray in our pipeline index.